| Pfizer Inc. and BioNTech SE now reign as champions in the race to clear a coronavirus vaccine on both sides of the Atlantic. On Friday, the partners received an emergency-use authorization from U.S. regulators, bringing the nation a much-needed tool as cases continue to skyrocket. Shipments to states of 2.9 million doses are expected imminently. The U.S. wants more—and wants it fast. Operation Warp Speed, the government effort to accelerate development and snap up Covid-19 shots, has purchased 100 million doses of the two-dose regimen. But it's currently in discussions with Pfizer to exercise options for additional supply. The negotiations ensued simultaneously as reports emerged last week that the U.S. had actually passed on an offer for more doses of the vaccine.  The Covid-19 vaccine created by Pfizer Inc. and BioNTech SE. Photographer: Owen Humphreys/PA Wire Health and Human Services Secretary Alex Azar said when the U.S. first clinched 100 million doses, Pfizer "refused to commit to any other production or delivery by a time certain." Come October, Pfizer still wouldn't share a date by which it could deliver more doses, Azar added. The Trump administration has threatened that it could invoke the Defense Production Act to ensure the American people get shots ASAP. One problem? Pfizer and BioNTech have other agreements to fulfill. BioNTech has assured that the pace of production is moving briskly. Next year, the companies will be able to meet their 1.3 billion dose objective, according to Chief Business Officer and Chief Commercial Officer Sean Marett. They've got sufficient raw materials, and are onboarding new production capacity. It's a massive undertaking: "This is a new technology, there does not exist a manufacturing network," Marett said. "We are building it." Government purchasers large and small are making demands: "Everybody wants all their doses on January 2nd of next year," the BioNTech executive said in an interview. "That's not practical." Output will increase throughout 2021, and both Pfizer and BioNTech are committed to the dosing schedules they've agreed to with the U.S., as well as with other countries, Marett said. "Both companies want to provide the vaccines fairly to all of those countries that want it," he said. "We have allocation based on such principles. We won't deviate from that."--Riley Griffin | 
⇉〖OpenLoad〗 2020 Superintelligence PelÃcula Completa En LÃnea released 2020. story: La vida de Carol Peters se trastorna cuando es selecci...
Post a Comment